



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid Drug Utilization Review (DUR) Board
Thursday, December 12, 2019, 2:00pm
DMAS 13th Floor Conference Room
Agenda

1. **Call to Order and Introductions** – Chethan Bachireddy, MD, Chief Clinical Innovation Officer, Chief Medical Officer, Chair
2. **Minutes** - Approval of Minutes from September 26, 2019 meeting
3. **RetroDUR Criteria Estimates**
4. **New Drugs - Grid**
 - a. Inrebic[®](fedratinib)
 - b. Nourianz[™] (istradefylline)
 - c. Nubeqa[®] (darolutamide)
 - d. Rozlytrek[™] (entrectinib)
 - e. Slynd[™] (drospirenone)
 - f. Temixys[™] (lamivudine and tenofovir disoproxil fumarate)
 - g. Turalio[™] (pexidartinib)
 - h. Xenleta[™] (lefamulin)
 - i. Xpovio[™] (selinexor)
 - j. Drug Updates: New Generics; New Dosage Form/ Strength/ Biosimilar; PDL-Eligible; Physician Administered Drugs.
5. **Physician-Administered Drugs**
 - a. Luxturna[®] (voretigene neparvovec-rzyl)
 - b. Zolgensma[®] (onasemnogene abeparvovec-xioi)
6. **Specialty Drugs**
 - a. Crizanlizumab IV
 - b. Semaglutide Oral
 - c. MRx Pipeline



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

- 7. Topics for Discussion**
 - a. Concurrent Use of Opioids and Benzodiazepines
 - b. SUPPORT Act Update
 - c. DUR Quarterly Newsletter
- 8. Surveillance**
 - a. Opioid Use with Risk Factors and No Naloxone
 - b. Opioid Use with Risk Factors and Getting Naloxone
- 9. Reports**
 - a. ProDUR
 - b. RetroDUR
 - c. Utilization Analysis
- 10. Other Business**
- 11. Adjournment**